In this scenario, targeting PI3K/AKT/mTOR has become of high interest in the field of cancer and CRC, with a number of anti IGF-1 antibodies and tyrosine kinases or AKT/mTOR inhibitors being tested in numerous clinical trials [155,156,157]. This evidence concerns the gene AKT1 and cancer.